The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Gene obtained from curated document aligns with the Allele Registry but not with ClinVar data
  • No CSPEC computed assertion could be determined for this classification!


Variant: NM_000488.4(SERPINC1):c.1171C>T (p.Arg391Ter)

CA343772824

2734038 (ClinVar)

Gene: SERPINC1 (HGNC:462)
Condition: antithrombin III deficiency (MONDO:0013144)
Inheritance Mode: Autosomal dominant inheritance
UUID: dcf417cb-44a7-42fd-ac34-f899ff29d765
Approved on: 2024-12-20
Published on: 2024-12-20

HGVS expressions

NM_000488.4:c.1171C>T
NM_000488.4(SERPINC1):c.1171C>T (p.Arg391Ter)
NC_000001.11:g.173907497G>A
CM000663.2:g.173907497G>A
NC_000001.10:g.173876635G>A
CM000663.1:g.173876635G>A
NC_000001.9:g.172143258G>A
NG_012462.1:g.14882C>T
ENST00000367698.4:c.1171C>T
ENST00000367698.3:c.1171C>T
ENST00000617423.4:c.560-4C>T
NM_000488.3:c.1171C>T
NM_001365052.1:c.1027C>T
NM_001365052.2:c.1027C>T
NM_001386302.1:c.1294C>T
NM_001386303.1:c.1252C>T
NM_001386304.1:c.1150C>T
NM_001386305.1:c.1114C>T
NM_001386306.1:c.955C>T
More

Pathogenic

Met criteria codes 5
PS4_Moderate PP4 PP1_Strong PM2_Supporting PVS1_Strong

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Thrombosis Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for SERPINC1 Version 1.0.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Thrombosis VCEP
The c.1171C>T (p.Arg391Ter) variant in SERPINC1 is a nonsense variant that may cause loss of function of the protein, however it is predicted to escape nonsense mediated decay and remove >10% of the protein (PVS1_Strong). At least one patient with this variant displayed an antithrombin activity level of < 0.8 IU/mL on repeated independent studies, which is highly specific for hereditary antithrombin deficiency (PP4, PMID:29153735). This variant has been reported in at least four more probands meeting an antithrombin activity level of < 0.8 IU/mL; due to the absence of specified repeat testing, crossed electrophoresis showing abnormal results and family members with reported antithrombin activity levels below the threshold three of these probands were scored at only half a point. (2.5 points) (PS4_Moderate; PMIDs:34207366, 8217824, 31030036, 23932013). The variant has been reported to segregate with autosomal dominant hereditary antithrombin deficiency in 15 affected family members from two families (PP1_Strong; PMIDs:34207366, 23932013). The highest population minor allele frequency in gnomAD v4.1 is 0.000001 (2/1179816 alleles) in European non-Finnish population, which is lower than the ClinGen Thrombosis VCEP threshold (<0.00002) for PM2_Supporting, meeting this criterion (PM2_Supporting). In summary, this variant meets the criteria to be classified as pathogenic for autosomal dominant hereditary antithrombin deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen Thrombosis VCEP: PVS1_Strong, PP4, PS4_Moderate, PP1_Strong, PM2_Supporting. (ClinGen Thrombosis Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for SERPINC1 Version 1.0.0; date of approval)
Met criteria codes
PS4_Moderate
This variant has been reported in at least four more probands meeting an antithrombin activity level of < 0.8 IU/mL; due to the absence of specified repeat testing, crossed electrophoresis showing abnormal results and family members with reported antithrombin activity levels below the threshold three of these probands were scored at only half a point. (2.5 points) (PS4_Moderate; PMIDs:34207366, 8217824, 31030036, 23932013).
PP4
At least one patient with this variant displayed an antithrombin activity level of < 0.8 IU/mL on repeated independent studies, which is highly specific for hereditary antithrombin deficiency (PP4, PMID:29153735).
PP1_Strong
The variant has been reported to segregate with autosomal dominant hereditary antithrombin deficiency in 15 affected family members from two families (PP1_Strong; PMIDs:34207366, 23932013).
PM2_Supporting
The highest population minor allele frequency in gnomAD v4.1 is 0.000001 (2/1179816 alleles) in European non-Finnish population, which is lower than the ClinGen Thrombosis VCEP threshold (<0.00002) for PM2_Supporting, meeting this criterion (PM2_Supporting).
PVS1_Strong
The c.1171C>T (p.Arg391Ter) variant in SERPINC1 is a nonsense variant that may cause loss of function of the protein, however it is predicted to escape nonsense mediated decay and remove >10% of the protein (PVS1_Strong).
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
ClinGen Terms of Use.
¤ Powered by BCM's Genboree.